Interactive Cardiovascular and Thoracic Surgery 2:558-562(2003)
© 2003 European Association of Cardio-Thoracic Surgery
Institutional review - Thoracic general |
Survival and postoperative complication in daily practice after neoadjuvant therapy in resectable stage IIIA-N2 non-small cell lung cancer
Fabrice Barlésia,*,
Christophe Doddolib,
Bruno Chetaillec,
Jean-Philippe Torred,
Roger Giudicellib,
Pascal Thomasb,
Jean-Pierre Kleisbauera and
Pierre Fuentesb
a Department of Thoracic Oncology, Sainte Marguerite Hospital, University of Méditerranée, Faculty of Medicine, Assistance Publique - Hôpitaux de Marseille, Marseille, France
b Department of Thoracic Surgery, Sainte Marguerite Hospital, University of Méditerranée, Faculty of Medicine, Assistance Publique - Hôpitaux de Marseille, Marseille, France
c Department of Pathology, Sainte Marguerite Hospital, University of Méditerranée, Faculty of Medicine, Assistance Publique - Hôpitaux de Marseille, Marseille, France
d Department of Medical Information, Timone Hospital, University of Méditerranée, Faculty of Medicine, Assistance Publique - Hôpitaux de Marseille, Marseille, France
* Corresponding author. Service d'Oncologie Thoracique, Département des Maladies Respiratoires, Hôpital Sainte-Marguerite, 270 Bd Sainte-Marguerite, 13274 Marseille Cedex 09, France. Tel.: +33-491-74-47-36; fax: +33-491-74-55-24
Fabrice.Barlesi{at}mail.ap-hm.fr
Regarding persisting controversies about neoadjuvant treatment (NT), we studied the impact of neoadjuvant therapy in daily practice. Patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) resected after NT were eligible. Data on preoperative treatments, surgical procedure, postoperative complications and survival were collected. Overall, 71 (60 men, median age of 60 years) patients met inclusion criteria. All patients received a two-drug platinum-based regimen (median of 2.5 cycles [2–4 cycles]) and 15 (21%) had an associated radiotherapy (20–40 Gy). Nine complete and 27 partial responses were achieved. Surgical procedure principally was a lobectomy (44%), a left (15.5%) or a right (27%) pneumonectomy. Operative mortality was 4.2% while 21 patients (29%) experienced postoperative complications. Median survival was 17 months (95% CI, 13–21 months) with 3- and 5-year survival rates of 24 and 13%, respectively. Five-year survival was worse if postoperative complication occurred (18 versus 0%,  ). Multivariate analysis showed male gender ( , 95% CI, 0.16–0.81,  ) and postoperative positive lymph node ( , 95% CI, 1.4–5.2,  ) to influence survival. In conclusion, achievement of a clinical and pathological response after NT for stage IIIA-N2 NSCLC patients enables a better survival. More efficient but also less toxic regimens of chemotherapy should be developed regarding its impact on long-term survival.
Key Words: Non-small cell lung cancer; Neoadjuvant chemotherapy; Pathological response; N2; Surgery; Postoperative complication
This article has been cited by other articles:
|
|
|
|
 
M. J. Krasna
COUNTERPOINT: Pneumonectomy after chemoradiation: the risks of trimodality therapy.
J. Thorac. Cardiovasc. Surg.,
August 1, 2009;
138(2):
295 - 299.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Cerfolio, L. Maniscalco, and A. S. Bryant
The Treatment of Patients with Stage IIIA Non-Small Cell Lung Cancer From N2 Disease: Who Returns to the Surgical Arena and Who Survives
Ann. Thorac. Surg.,
September 1, 2008;
86(3):
912 - 920.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Barlesi, C. Doddoli, J.-P. Torre, R. Giudicelli, P. Fuentes, P. Thomas, and P. Astoul
Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy
Eur. J. Cardiothorac. Surg.,
October 1, 2005;
28(4):
629 - 634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
